Kentucky Retirement Systems Has $2.34 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Kentucky Retirement Systems lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,901 shares of the medical research company’s stock after selling 164 shares during the period. Kentucky Retirement Systems’ holdings in IQVIA were worth $2,339,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in IQV. FMR LLC increased its stake in shares of IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of IQVIA in the third quarter worth about $147,683,000. JPMorgan Chase & Co. increased its stake in shares of IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Nordea Investment Management AB increased its stake in shares of IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares during the period. Finally, KBC Group NV increased its stake in shares of IQVIA by 68.5% in the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after purchasing an additional 250,458 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The shares were acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is owned by company insiders.

IQVIA Stock Down 1.6 %

Shares of IQV opened at $190.94 on Friday. The company has a market capitalization of $33.62 billion, a P/E ratio of 25.46, a PEG ratio of 1.99 and a beta of 1.48. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The business’s 50 day simple moving average is $199.57 and its 200-day simple moving average is $216.49.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IQV. Stephens began coverage on IQVIA in a research note on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research note on Monday, February 10th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. TD Cowen lowered their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Bank of America lowered their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.